SAREPTA THERAPEUTICS, INC. Payment for Debt Extinguishment or Debt Prepayment Cost
SAREPTA THERAPEUTICS, INC. (SRPT) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2025-02-28
- SAREPTA THERAPEUTICS, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2023-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2021-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. payment for debt extinguishment or debt prepayment cost for the quarter ending 2018-12-31 was $144.00K.
- SAREPTA THERAPEUTICS, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2024 was $0.00.
- SAREPTA THERAPEUTICS, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2022 was $25.36M.
- SAREPTA THERAPEUTICS, INC. payment for debt extinguishment or debt prepayment cost for fiscal 2021 was $0.00.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-01 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $25.36M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $25.36M 10-Q · filed 2023-11-01 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-02 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | ||
| 2018-12-31 | $144.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.13M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $1.99M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |